Author

C. M. Poh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:database / resource· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Y.-P. Lee· 3 shared G. Carissimo· 3 shared L. Renia· 3 shared R. S.-L. Chee· 3 shared S. N. Amrun· 3 shared B. E. Young· 2 shared C.-I. Wang· 2 shared D. C. Lye· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Y.-P. Lee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Data-driven analysis of COVID-19 reveals specific severity patterns distinct from the temporal immune response

J. Lim, G. Carissimo, Y.-H. Chan, S.-W. Fong, W. W. Lee, S.-Y. Tan, D. C. Lye, B. E. Young, L. Renia, L. Fong-Poh NG, O. Rotzschke, K. J. Puan, L. W. Wang, K. W. W. Teng, C. Y. Loh, , B. Lee

The paper identifies immune signatures associated with COVID-19 severity and temporality, revealing distinct patterns and providing tools for data analysis.

bioRxiv · Feb 10, 2021 · PreprintImmunology

Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant.

C. Y.-P. Lee, S. N. Amrun, R. S.-L. Chee, Y. S. Goh, T. M. Mak, S. Octavia, N. Yeo, Z. W. Chang, M. Z. Tay, A. Torres, G. Carissimo, C. M. Poh, S.-W. Fong, B. Wang, S. Lee, , L. F. P. Ng

This study shows that antibodies from early SARS-CoV-2 infections neutralize both the original and D614G variants, though neutralizing capacity decreases over time.

bioRxiv · Oct 8, 2020 · PreprintImmunology

Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein

C. M. Poh, G. Carissimo, W. Bei, S. N. Amrun, C. Y.-P. Lee, R. S.-L. Chee, N. K.-W. Yeo, W.-H. Lee, Y.-S. Leo, M. I.-C. Chen, S.-Y. Tan, L. Y. A. Chai, S. Kalimuddin, S.-Y. Thien, B. E. Young, , L. F. Ng

The paper identifies two immunodominant linear epitopes on the SARS-CoV-2 spike protein that are targets of potent neutralizing antibodies in convalescent patient sera.

bioRxiv · Mar 30, 2020Immunology